Part 6/9:
At ASCO, initial data presentations showed that Rova-T could outperform existing therapies by reducing tumor sizes effectively. However, Harjes raised concerns over whether these results were substantial enough considering the steep price tag of the acquisition. While positive, the outcomes may not be transformative for AbbVie’s investment, leaving investors pondering about the drug's future potential and whether it is adaptable for other types of cancer expressing the DLL3 protein.
Campbell countered Harjes' concerns, noting AbbVie's management is optimistic about the drug's future, suggesting a potential for significant sales if Rova-T succeeds.